Allurion Technologies Inc. (ALUR)

Allurion Technologies Inc. is dedicated to combating obesity through its innovative weight loss platform, the Allurion Program. This platform features a swallowable intragastric balloon and AI-powered remote patient monitoring tools, offering a comprehensive approach to weight management.

45/100 AI Score MCap 13M Vol 159K

Company Overview

CEOShantanu K. Gaur
Employees134
HeadquartersNatick, MA, US
IPO Year2021

Allurion Technologies Inc. offers a disruptive, procedure-less weight loss platform featuring a swallowable intragastric balloon and AI-powered remote monitoring, positioning it as a leader in the evolving obesity treatment market with a focus on patient convenience and comprehensive care.

Investment Thesis

Allurion Technologies presents a compelling investment opportunity within the growing obesity treatment market. The company's innovative, procedure-less Allurion Program offers a unique value proposition, differentiating it from traditional weight loss solutions. With a gross margin of 61.0%, Allurion demonstrates strong potential for profitability as it scales its operations. The increasing prevalence of obesity worldwide, coupled with growing patient demand for non-surgical weight loss options, creates a favorable market environment for Allurion. Key growth catalysts include expanding market access, increasing adoption of the Allurion Virtual Care Suite, and continued innovation in its product offerings. While the company currently operates with a negative P/E ratio of -1.97 and a negative profit margin of -251.6%, strategic investments in sales, marketing, and product development are expected to drive revenue growth and improve profitability in the long term.

Key Highlights

  • Market Cap of $0.01B reflects the company's current valuation and potential for growth within the obesity treatment market.
  • Gross Margin of 61.0% indicates strong pricing power and efficient cost management in the delivery of the Allurion Program.
  • P/E Ratio of -1.97 suggests the company is currently not profitable, but reflects its growth stage and investments in future expansion.
  • Beta of -0.47 indicates the stock is less volatile than the market, potentially offering a more stable investment option.
  • The Allurion Program's unique, procedure-less approach differentiates it from competitors and addresses a growing demand for non-surgical weight loss solutions.

Competitors

Strengths

  • Innovative, procedure-less weight loss solution.
  • Comprehensive Allurion Program with virtual care suite.
  • Strong gross margin.
  • Growing brand recognition.

Weaknesses

  • Negative P/E ratio and profit margin.
  • Relatively small market capitalization.
  • Limited geographic reach compared to larger competitors.
  • Reliance on a single product (Allurion Balloon).

Catalysts

  • Upcoming: Expansion into new geographic markets, increasing revenue and market share.
  • Ongoing: Increasing adoption of the Allurion Virtual Care Suite, driving recurring revenue.
  • Ongoing: Strategic partnerships with healthcare providers, expanding reach and credibility.
  • Upcoming: Positive clinical trial results demonstrating the efficacy of the Allurion Program.

Risks

  • Potential: Competition from established pharmaceutical and medical device companies.
  • Potential: Regulatory hurdles and reimbursement challenges in new markets.
  • Potential: Product recalls or safety concerns affecting brand reputation.
  • Ongoing: Economic downturns affecting consumer spending on weight loss solutions.
  • Ongoing: Dependence on the Allurion Balloon as the primary revenue driver.

Growth Opportunities

  • Expanding Market Access: Allurion has the opportunity to expand its geographic footprint by entering new markets and securing regulatory approvals in key regions. This includes targeting countries with high obesity rates and a growing demand for non-surgical weight loss solutions. Successful market expansion can significantly increase Allurion's revenue and market share, potentially reaching a multi-billion dollar market over the next 3-5 years.
  • Increasing Adoption of the Allurion Virtual Care Suite: The Allurion Virtual Care Suite offers a comprehensive platform for remote patient monitoring, behavior change support, and telehealth services. By increasing adoption of this suite among existing and new patients, Allurion can enhance patient engagement, improve health outcomes, and generate recurring revenue streams. This represents a significant growth opportunity with a potential market size of hundreds of millions of dollars annually.
  • Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and physicians can accelerate the adoption of the Allurion Program and expand its reach to a wider patient population. These partnerships can provide Allurion with access to established referral networks and enhance its credibility within the medical community. The partnership market could be worth tens of millions in revenue over the next few years.
  • Continued Innovation in Product Offerings: Allurion can maintain its competitive edge by investing in research and development to enhance its existing products and develop new solutions for weight loss and related health conditions. This includes exploring new technologies, improving the efficacy of the Allurion Balloon, and expanding the capabilities of the Allurion Virtual Care Suite. Innovation could unlock a market potential of hundreds of millions within 5 years.
  • Direct-to-Consumer Marketing and Sales: Allurion can leverage digital marketing channels and direct-to-consumer advertising to raise awareness of the Allurion Program and drive patient demand. This includes targeting overweight individuals who are actively seeking weight loss solutions and educating them about the benefits of Allurion's procedure-less approach. A successful direct-to-consumer strategy can significantly increase Allurion's customer base and revenue, tapping into a market worth billions.

Opportunities

  • Expanding market access to new geographies.
  • Increasing adoption of the Allurion Virtual Care Suite.
  • Strategic partnerships with healthcare providers.
  • Continued innovation in product offerings.

Threats

  • Competition from established pharmaceutical and medical device companies.
  • Regulatory hurdles and reimbursement challenges.
  • Potential for product recalls or safety concerns.
  • Economic downturns affecting consumer spending on weight loss solutions.

Competitive Advantages

  • Proprietary Technology: The Allurion Balloon is a patented, swallowable intragastric balloon that does not require surgery or endoscopy for placement or removal.
  • Comprehensive Program: The Allurion Program offers a holistic approach to weight loss, combining the balloon with remote patient monitoring, behavior change support, and telehealth services.
  • Brand Recognition: Allurion has established a strong brand presence in the non-surgical weight loss market.
  • Established Partnerships: Allurion has cultivated relationships with healthcare providers, expanding its reach and credibility.

About

Founded with the mission of ending obesity, Allurion Technologies Inc. has pioneered a unique approach to weight loss through its innovative Allurion Program. The cornerstone of this program is the Allurion Balloon, a swallowable, procedure-less intragastric balloon designed to promote weight loss in overweight individuals. Unlike traditional gastric balloons that require endoscopic placement and removal, the Allurion Balloon is easily administered and naturally excreted after approximately four months. Beyond the balloon, the Allurion Program incorporates the Allurion Virtual Care Suite, a comprehensive suite of AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth. This virtual care suite provides patients with continuous support and guidance throughout their weight loss journey, fostering long-term behavioral changes and improved health outcomes. Headquartered in Natick, Massachusetts, Allurion is focused on expanding its global reach and solidifying its position as a leader in the non-surgical weight loss market. The company's commitment to innovation and patient-centric care has enabled it to establish a strong presence in key markets worldwide, offering a compelling alternative to traditional weight loss methods.

What They Do

  • Develop a swallowable, procedure-less intragastric balloon for weight loss.
  • Offer a comprehensive weight loss platform called the Allurion Program.
  • Provide AI-powered remote patient monitoring tools.
  • Deliver a proprietary behavior change program.
  • Offer secure messaging and video telehealth services.
  • Focus on treating overweight and obese individuals.
  • Provide a non-surgical alternative to traditional weight loss methods.

Business Model

  • Sales of the Allurion Balloon to healthcare providers.
  • Subscription fees for the Allurion Virtual Care Suite.
  • Partnerships with hospitals and clinics.
  • Direct-to-consumer marketing and sales.

Industry Context

Allurion Technologies operates within the medical device industry, specifically targeting the obesity treatment market. This market is experiencing significant growth, driven by the rising prevalence of obesity worldwide and increasing awareness of its associated health risks. The competitive landscape includes pharmaceutical companies offering weight loss drugs, medical device companies providing surgical solutions like gastric bypass, and other companies offering intragastric balloons. Allurion differentiates itself with its procedure-less, swallowable balloon and comprehensive virtual care program, appealing to patients seeking a less invasive and more convenient weight loss option.

Key Customers

  • Overweight and obese individuals seeking weight loss solutions.
  • Healthcare providers, including physicians, hospitals, and clinics.
  • Patients looking for non-surgical alternatives to traditional weight loss methods.
  • Individuals seeking a comprehensive weight loss program with remote support.
AI Confidence: 71% Updated: 2/9/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $3M -$12M $0.00
Q2 2025 $3M -$9M $0.00
Q1 2025 $6M $7M $0.00
Q4 2024 $6M -$21M $0.00

Source: Company filings

Chart & Info

Price Chart

Allurion Technologies Inc. (ALUR) stock price: $1.69 (+0.24, +16.55%)

Why Bull

  • •Allurion has seen strong insider buying recently, indicating confidence from management in the company's future prospects.
  • •Social sentiment has been increasingly positive, with community discussions highlighting the innovative nature of Allurion's weight loss solutions.
  • •Recent partnerships and collaborations have generated buzz, suggesting a growing market presence and potential for expansion.
  • •The healthcare sector's focus on obesity solutions aligns with Allurion's offerings, positioning the company well in a high-demand area.

Why Bear

  • •Some analysts express concerns over the competitive landscape, with several new entrants in the weight loss technology market potentially impacting Allurion's market share.
  • •Community sentiment has shown volatility, with mixed opinions regarding the sustainability of recent growth and product efficacy.
  • •Recent regulatory challenges have raised questions about the speed of product approvals, which could hinder future growth opportunities.
  • •Investors are wary of the company's cash burn rate, leading to uncertainty about its financial health in the near term.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
158,139

Rationale

AI-generated technical analysis for ALUR including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Allurion Technologies Inc. (ALUR) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for ALUR.

Make a Prediction

Set your price target for Allurion Technologies Inc. (ALUR), choose a timeframe, and track your prediction accuracy.

Current price: $1.69

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALUR.

Price Targets

Wall Street price target analysis for ALUR.

Insider Flow (30d)

Davin Michael R
Insider
2 months ago
SOLD
1,606 shares
$2K

MoonshotScore

44.5/100

Score Factors

  • Revenue Growth 2/100

    Revenue declined -39.9% YoY, signaling shrinking demand or market headwinds.

  • Gross Margin 10/100

    Gross margin of 61.0% shows excellent pricing power and a strong competitive moat.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates ALUR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Allurion Technologies Inc. do?

Allurion Technologies Inc. is dedicated to ending obesity by offering a comprehensive weight loss platform called the Allurion Program. This program features the Allurion Balloon, a swallowable, procedure-less intragastric balloon that promotes weight loss. In addition to the balloon, Allurion provides the Allurion Virtual Care Suite, which includes AI-powered remote patient monitoring tools, a behavior change program, and telehealth services, offering a holistic approach to weight management. The company focuses on providing a convenient and effective alternative to traditional weight loss methods.

Is ALUR stock a good buy?

ALUR stock presents a mixed investment profile. The company's innovative, procedure-less weight loss solution and strong gross margin of 61.0% are positive indicators. However, the negative P/E ratio of -1.97 and profit margin of -251.6% reflect the company's current growth stage and investments in expansion. Potential investors should consider the company's growth opportunities, such as expanding market access and increasing adoption of the Allurion Virtual Care Suite, while also being aware of the risks associated with competition and regulatory hurdles. A balanced analysis of these factors is crucial before making an investment decision.

What are the main risks for ALUR?

Allurion Technologies faces several key risks. The company operates in a competitive market with established pharmaceutical and medical device companies. Regulatory hurdles and reimbursement challenges in new markets could also hinder growth. Product recalls or safety concerns related to the Allurion Balloon could negatively impact the company's brand reputation. Additionally, economic downturns could affect consumer spending on weight loss solutions. Finally, the company's dependence on the Allurion Balloon as the primary revenue driver poses a risk if alternative weight loss solutions gain popularity.

Is ALUR a good stock to buy?

Whether ALUR is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the ALUR MoonshotScore?

The MoonshotScore for ALUR is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is ALUR data updated?

ALUR stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to ALUR is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for ALUR?

Growth catalysts for Allurion Technologies Inc. (ALUR) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Allurion Technologies Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are ALUR's main competitors?

Allurion Technologies Inc. (ALUR) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether ALUR has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about ALUR?

Wall Street analyst coverage for ALUR includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is ALUR's market cap?

Market capitalization (market cap) for ALUR is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows ALUR's current market cap alongside enterprise value and other valuation metrics.

How has ALUR stock performed recently?

ALUR's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing ALUR's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in ALUR?

Key risk categories for ALUR include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures ALUR's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling ALUR?

Insider trading activity for ALUR tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is ALUR a good stock for beginners?

Allurion Technologies Inc. (ALUR) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is ALUR for first-time investors?

Every stock carries risk, including Allurion Technologies Inc. (ALUR). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ALUR.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Financial data is based on available information and may be subject to change.
  • The obesity treatment market is dynamic and subject to evolving trends and regulations.
Data Sources
profilefundamentalsexistingCopy